Certolizumab Pegol
Certolizumab Pegol
Definition
A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile.
Also known as CDP 870, CDP870, CERTOLIZUMAB PEGOL, Cimzia, CZP, PHA-738144 — per NCIT
Also identified as
- ATC L04AB05 per RXNORM
- NCIT NCIT:C80972 per NCIT
- SCTID 430306004 per RXNORM
- SCTID 430307008 per RXNORM
- UNII UMD07X179E per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Ankylosing spondylitis | may treat | MEDRT · Public domain (U.S. Government work) |
| Crohn's disease | may treat | MEDRT · Public domain (U.S. Government work) |
| Psoriatic arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
| Rheumatoid arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Alimentary part of gastrointestinal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Bone element | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Intestine | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Skeletal joint | may treat a disease of this organ | DERIVED · CC BY 4.0 |
5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.